CMS Proposal Would Leave Millions of Patients Without Access to FDA Approved Treatments
Date: 3/24/2022
LuMind IDSC President and CEO Hampus Hillerstrom contributed to UsAgainstAlzheimer’s and the Global Alzheimer’s Platform Foundation’s recent statement in opposition to the proposed rule by the Centers for Medicare and Medicaid Services (CMS) that would deny millions of patients–including people with Down syndrome–access to life-saving Alzheimer’s treatments and clinical trials.
March 24, 2022